InvestorsHub Logo
Followers 14
Posts 1446
Boards Moderated 0
Alias Born 02/28/2011

Re: early_retirement2 post# 2263

Monday, 10/31/2016 9:38:03 AM

Monday, October 31, 2016 9:38:03 AM

Post# of 3353
Patent News

multiple websites have the same info. here's one of them;

http://www.prnewswire.com/news-releases/brainstorm-granted-united-states-patent-for-its-stem-cell-technology-300353380.html


BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) announced that it has been granted United States Patent No. 9,474,787 titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."

The allowed claims cover mesenchymal stem cells that secrete neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF), as well as a pharmaceutical compositions comprising these factors.

"We are pleased that the US Patent Office continues to recognize the innovative nature of NurOwn®, our proprietary, differentiated mesenchymal stem cells, for use as a pharmaceutical," commented BrainStorm's CEO Chaim Lebovits. "This patent, along with the previously granted patents and patent applications, is part of our strategy to aggressively establish a broad portfolio of intellectual property to protect all of our commercially important discoveries."

This patent is the result of Brainstorm's ongoing joint development of NurOwn® together with the Tel Aviv University, and reflects the collaboration between the company and the laboratory of Prof. Dani Offen, the company's chief scientist.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BCLI News